Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
NCT ID: NCT01720576
Last Updated: 2013-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2012-10-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Dose 1 of REGN1033 (SAR391786) or Placebo
REGN1033 (SAR391786)
Placebo
Cohort 2
Dose 2 of REGN1033 (SAR391786) or Placebo
REGN1033 (SAR391786)
Placebo
Cohort 3
Dose 3 of REGN1033 (SAR391786) or Placebo
REGN1033 (SAR391786)
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REGN1033 (SAR391786)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A subject must meet the following criteria to be eligible for inclusion in the study:
1. Sexually active males willing to use contraceptives during the study and through 4 months after the study.
2. Female subjects not of child bearing potential (surgically sterile or postmenopausal for longer than 1 year)
3. Body mass index (BMI) between 18.5 and 32 kg/m2 inclusive
4. Willing to maintain current diet and exercise routine for the duration of the study
5. Willing and able to return for all clinic visits and complete all study-related procedures
6. Able to read and understand, and willing to sign the ICF
Exclusion Criteria
2. Evidence of malnutrition
3. Cachexia of any cause
4. Evidence or history of muscle diseases or weakness with the exception of age related muscle loss
5. Limb amputation
6. Immobilization, surgical procedure, fracture, or trauma to the upper or lower limb within 6 months
7. History or evidence of heart diseases including but not limited to coronary heart disease with/without history of myocardial infarction, chronic or acute heart failure (New York Heart Association \[NYHA\] stage 2-4), cardiac arrhythmia with clinical symptoms, valvular heart disease, and cardiac hypertrophy of clinical significance
8. Women of childbearing potential (not surgically sterile or amenorrheic for at least 12 months if postmenopausal)
9. Uncontrolled diabetes defined as HbA1C \> 7.5 at screening; if taking oral hypoglycemic drugs, have to be on stable doses of medication for more than 3 months. Diabetics using insulin are excluded
10. Asthmatic subjects with current or recurring symptoms within 1 year.
11. History of, COPD, chronic kidney disease, cancer except primary basal-cell skin cancer that has been adequately treated
12. Neurological injury (eg, stroke) within 1 year
13. Abnormal or uncontrolled blood pressure at screening visit defined as diastolic BP \>95 and/or systolic BP \>160 mm Hg; if taking hypertensive medication, have to be on stable doses of medication for more than 3 months
14. Hepatic transaminases (ALT and or AST) \> 2X ULN
15. Reduced renal function as defined by eGFR\<60 mL/min
16. Current smokers or previous smokers who stopped smoking within 6 months
17. Current or recent history (within 1 year of screen) of alcohol or drug abuse
18. History of hypersensitivity response to any biologics
19. History of hypersensitivity to doxycycline or other tetracycline antibiotics
20. Current or recent participation in any clinical trial (within 30 days of small molecular drugs or within 3 months of biologics)
21. Exposure within 3 months to approved biological drugs. (The name of the drug and duration of previous exposure will be recorded). Vaccines are allowed.
22. Sexually active men\* who are unwilling to practice adequate contraception during the study
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trial Management
Role: STUDY_DIRECTOR
Regeneron Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Daytona Beach, Florida, United States
Evansville, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R1033-HV-1204
Identifier Type: -
Identifier Source: org_study_id